ZA921660B - Antiviral nucleoside combination - Google Patents

Antiviral nucleoside combination

Info

Publication number
ZA921660B
ZA921660B ZA921660A ZA921660A ZA921660B ZA 921660 B ZA921660 B ZA 921660B ZA 921660 A ZA921660 A ZA 921660A ZA 921660 A ZA921660 A ZA 921660A ZA 921660 B ZA921660 B ZA 921660B
Authority
ZA
South Africa
Prior art keywords
antiviral nucleoside
combinations
combination
nucleoside combination
antiviral
Prior art date
Application number
ZA921660A
Other languages
English (en)
Inventor
George Robert Painter Iii
Phillip Allen Furman
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA921660B publication Critical patent/ZA921660B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA921660A 1991-03-06 1992-03-05 Antiviral nucleoside combination ZA921660B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919104740A GB9104740D0 (en) 1991-03-06 1991-03-06 Antiviral nucleoside combination

Publications (1)

Publication Number Publication Date
ZA921660B true ZA921660B (en) 1993-09-06

Family

ID=10691101

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA921660A ZA921660B (en) 1991-03-06 1992-03-05 Antiviral nucleoside combination

Country Status (25)

Country Link
US (2) US5234913A (enExample)
EP (1) EP0574457B1 (enExample)
JP (1) JP3442773B2 (enExample)
KR (1) KR100225986B1 (enExample)
AT (1) ATE185483T1 (enExample)
AU (1) AU668860B2 (enExample)
CA (1) CA2105487C (enExample)
CZ (1) CZ283185B6 (enExample)
DE (1) DE69230140T2 (enExample)
DK (1) DK0574457T3 (enExample)
ES (1) ES2138969T3 (enExample)
GB (1) GB9104740D0 (enExample)
GR (1) GR3032299T3 (enExample)
HU (1) HU219492B (enExample)
IE (1) IE920702A1 (enExample)
IL (1) IL101145A (enExample)
MY (1) MY108638A (enExample)
NZ (1) NZ241842A (enExample)
PT (1) PT100199B (enExample)
RU (1) RU2110993C1 (enExample)
SK (1) SK279767B6 (enExample)
TW (1) TW199861B (enExample)
UA (1) UA29429C2 (enExample)
WO (1) WO1992015309A1 (enExample)
ZA (1) ZA921660B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ATE131730T1 (de) * 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
AU2119695A (en) * 1994-03-16 1995-10-03 Tanox Biosystems, Inc. Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
DE69718168T2 (de) * 1996-06-25 2003-10-23 Glaxo Group Ltd., Greenford Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
EP0938321B1 (en) * 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO1998041522A1 (en) 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ,インコーポレイティド 他の抗ウイルス剤との組合せにおけるmkc−442の使用
US6040434A (en) * 1997-12-01 2000-03-21 Inaba; Tadanobu Aldehyde oxidase inhibitors for treatment of aids
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
EP1535921A1 (en) 1998-08-12 2005-06-01 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
EP1382343B1 (en) * 1998-11-02 2010-02-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2867970A1 (en) * 2001-03-01 2002-09-12 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
IE56503B1 (en) * 1985-03-16 1991-08-14 Wellcome Found Antiviral nucleosides
US4874751A (en) * 1985-03-16 1989-10-17 Burroughs Wellcome Co. Antibacterial treatment
FI87783C (fi) * 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
NZ222695A (en) * 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
JPH04501854A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IT1249019B (it) * 1990-06-28 1995-02-11 Lamberti S P A L Emulsione acquosa di resine filmogene per la finitura di pelli, cuoio e croste di pelle e relativo procedimento di applicazione
CA2095613C (en) * 1990-11-13 2001-01-02 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE131730T1 (de) * 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen

Also Published As

Publication number Publication date
JPH06506199A (ja) 1994-07-14
SK279767B6 (sk) 1999-03-12
EP0574457B1 (en) 1999-10-13
NZ241842A (en) 1994-08-26
GR3032299T3 (en) 2000-04-27
UA29429C2 (uk) 2000-11-15
AU1351292A (en) 1992-10-06
PT100199A (pt) 1993-07-30
EP0574457A1 (en) 1993-12-22
AU668860B2 (en) 1996-05-23
PT100199B (pt) 1999-06-30
HUT72460A (en) 1996-04-29
RU2110993C1 (ru) 1998-05-20
DE69230140D1 (de) 1999-11-18
WO1992015309A1 (en) 1992-09-17
IL101145A0 (en) 1992-11-15
US6107288A (en) 2000-08-22
SK95193A3 (en) 1994-01-12
CA2105487C (en) 2002-09-24
CZ183693A3 (en) 1994-06-15
CZ283185B6 (cs) 1998-01-14
US5234913A (en) 1993-08-10
JP3442773B2 (ja) 2003-09-02
ES2138969T3 (es) 2000-02-01
DK0574457T3 (da) 2000-04-17
HU9302496D0 (en) 1993-11-29
HK1004189A1 (en) 1998-11-20
HU219492B (hu) 2001-04-28
KR100225986B1 (ko) 1999-10-15
IE920702A1 (en) 1992-09-09
ATE185483T1 (de) 1999-10-15
MY108638A (en) 1996-10-31
CA2105487A1 (en) 1992-09-07
GB9104740D0 (en) 1991-04-17
TW199861B (enExample) 1993-02-11
DE69230140T2 (de) 2000-04-06
IL101145A (en) 1996-08-04

Similar Documents

Publication Publication Date Title
ZA921660B (en) Antiviral nucleoside combination
AU591125B2 (en) Therapeutic nucleosides
RU93045710A (ru) Противовирусная нуклеозидная композиция, способ ее получения и способ лечения
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
MY107843A (en) Anti-viral compounds.
DE69716135D1 (en) In 6-position durch thio substituierte paclitaxele
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
DE2862409D1 (en) Pharmaceutical formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders
GR3024699T3 (en) Use of dideoxy nucleoside analogues in the treatment of viral infections.
GB8822546D0 (en) Antiviral combinations
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
MY105855A (en) Therapeutic nucleotides.
GB8926595D0 (en) Pharmaceutical compositions for use in the treatment herpes simplex virus infections
FI950533L (fi) Seco-nukleosidien liponulkeotidit, niiden valmistaminen sekä niiden käyttö virusten vastaisina lääkkeinä
MY111746A (en) Therapeutic nucleosides.
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
AP9801307A0 (en) Use of 3-amino-4-hydroxbenzoic acid for treatment of retroviral infections.
MY104976A (en) Antiviral compounds
IL90894A0 (en) 6-mercaptopurine derivatives,the preparation thereof and the use thereof for controlling retrovirus infections
ZA928197B (en) Bemzodiazepine derivatives, compositions containing them and their use in therapy.